FAZ 053 - Novartis Pharmaceuticals

Drug Profile

FAZ 053 - Novartis Pharmaceuticals

Alternative Names: FAZ-053

Latest Information Update: 01 Dec 2016

Price : $50

At a glance

  • Originator Novartis Pharmaceuticals
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 14 Oct 2016 Preclinical trials in Solid tumours in Switzerland (Parenteral) before Octobr 2016 (NCT02936102)
  • 14 Oct 2016 Novartis Pharmaceuticals plans a phase I trial for Solid tumours (Monotherapy, Combination therapy, Late-stage, Metastatic disease) in USA, Taiwan, Japan, Canada, Israel, Singapore, South Korea, Germany, Spain, France and Italy (NCT02936102)
  • 01 Oct 2016 Phase-I clinical trials in Solid tumours (Monotherapy, Combination therapy, Late-stage disease, Metastatic disease) in Canada, Singapore (IV) (NCT02936102)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top